icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
1GAq7Tt2tuEHdHcr